Medications and Nightmares: How Common Drugs Can Cause Restless Sleep

?? Welcome to this edition of Sleepletter? where we offer you easy-to-read insights from the latest research papers from the field of sleep neurobiology and clinical sleep medicine. Sign up to also receive Sleepletter by email .

?? Want to optimize your sleep? Join us for exclusive seminars and events that unveil the science of sleep and receive personalized, actionable and science-backed recommendations how to improve sleep. Subscribe here !

Every night, our brains progress through regular 90-minute sleep cycles beginning with light non-REM stages before reaching physically restoring deep delta wave sleep. Thereafter, REM cycles commence, characterized by paralysis of voluntary muscles, faster breathing, darting eyes and dreaming. Most dreaming occurs during rapid eye movement (REM) sleep, which repeats cyclically throughout the night, with longer REM duration in the second part of the night. During REM, the brain is highly active and dreams support processing emotional memories consolidated within neural circuits involved in learning and cognition. REM cycles last around 5-30 minutes and alternate with non-REM sleep every 90 minutes. Key neurotransmitters driving REM cycles include acetylcholine, serotonin, histamine, orexin, norepinephrine , and cyclin-dependent kinase signaling cascades. REM dreaming is crucial for emotional regulation, memory consolidation, and overall restorative sleep. However, growing evidence indicates commonly prescribed medications can directly disrupt normal REM signaling, frequently increasing nightmares or intensely vivid dreams as unintended consequences impeding restorative sleep. So how can medications increase the risk of nightmares? Let’s dig deep into the drugs most commonly associated with nightmares.

Multiple studies reviewed indicate different classes of antidepressants may increase the frequency and intensity of nightmares in some patients. Selective serotonin reuptake inhibitors (SSRIs) in particular seem to have this potential. A study on 21 depressive patients found significantly reduced dream recall frequency during treatment with the SSRI fluoxetine or the atypical antidepressant nefazodone, though 4 fluoxetine patients showed increased recall. Another study showed 15 patients on SSRIs/SNRIs had more frequent nightmares compared to being on bupropion or no antidepressant. Withdrawal from the monoamine oxidase inhibitor phenelzine was associated with frightening dreams in some cases. Across 25 case studies , 27 out of 35 patients reported new or worsened nightmares or other negative dream changes from starting or stopping an antidepressant. Multiple case reports specifically linked the SSRIs fluoxetine, paroxetine, and sertraline to nightmares.

What could be the biological mechanism behind this? Quite ccomplicated, to say the least. A large review article suggests serotonin reuptake inhibitors may have a particular potential to cause nightmares that does not necessarily depend on dosage. This may be related to effects on REM sleep, as SSRIs can reduce REM sleep and induce signs of REM sleep behavior disorder. However, mechanisms beyond just REM sleep suppression seem to be involved, as atypical antidepressants with little REM effects like nefazodone still reduced dream recall. Tricyclic antidepressants were linked to improved dream quality and emotions, yet withdrawal could also elicit nightmares. Finally, since antidepressants (or withdrawal from them) alters levels of neurotransmitters such as serotonin, dopamine and noradrenaline, which play important roles in sleep, one can assume that this chance can have an impact on nightmares.

Apart from antidepressants, beta-blockers, which are used for a variety of conditions, including heart disorders and high blood pressure, have extensive data linking them to increased nightmares . Multiple clinical trials with various common beta-blockers (e.g. propranolol, atenolol) demonstrate a robust correlation with patient reports of unpleasant dreams or nightmares. As these drugs target norepinephrine receptors involved in REM regulation, it strongly indicates norepinephrine's role in dreaming. Beyond adrenergic modulation, dopamine influencing medications also frequently lead to vivid, disturbing dreams as a side effect. Dopamine agonists for Parkinson’s disease (e.g. pramipexole), as well as amphetamine stimulants overactivate dopamine drive, though by differing mechanisms which might lead to nightmares.

Multiple clinical trials and case studies demonstrate antibiotics (ciprofloxacine , erythromycin ) and antivirals (efavirenz ) contributing to vivid, unpleasant dreams or nightmares in some patients. The proposed mechanism implicates how inflammatory responses during illness fundamentally alters sleep architecture. Infectious agents themselves as well as cytokine release disrupt normal REM cycles. Therefore, pharmacological agents that further modulate inflammatory signals may compound sleep interruptions.

In summary, numerous common drug classes have been linked to increased nightmares by disrupting normal REM sleep signaling—including antidepressants (especially SSRIs), beta-blockers, dopamine agonists, and antibacterial/antivirals. The mechanisms are complex, but involve neurochemical imbalance of key transmitters like serotonin, norepinephrine and dopamine that regulate sleep cycles. Patients and providers should monitor for changes in dream patterns when starting or stopping these agents. Safeguarding healthy sleep whenever possible, while treating the underlying condition, remains important for wellbeing and quality of life.

***

About the author

Alen Juginovi? is a medical doctor and postdoctoral researcher in the Department of Neurobiology at Harvard Medical School studying the effect of poor sleep quality on health. He is public and keynote speaker and teacher at Harvard College. He and his team also organize international award-winning projects such as conferences which attracted 2400+ participants from 30+ countries, 10 Nobel laureates and major leaders in medicine (Plexus Conference ), collaborative research projects, charity concerts and other events. He co-founded Med&X Association , a non-profit organization that organizes conferences with Nobel laureates and partners with leading universities and hospitals around the world to help accelerate the development of talented medical students and professionals. Feel free to contact Alen via LinkedIn for any inquiries.